A small global launch team solicited Uptake Strategies’ help to create a global launch strategy, plan and set of tactics for the 3 years ahead of the global launch of a new oral medication for a specialist condition.
The team was very small despite the large commercial opportunity, due to the risk in the potential outcomes of the final Phase 3 clinical trials and strong competitor pipeline.
Create a series of global strategy and planning working sessions in the US and Europe with the core global team members, using the company’s launch and global planning resources.
Uptake Strategies supported with assembling materials, designing and facilitating the launch sessions, communicating with senior management and collating a global launch strategy and plan with key decision gates / milestones.
A full programme of patient / prescriber / payer / insights across 10 key global markets were analysed, and cross-functional launch plans were created across pricing / access, medical, marketing / commercial, patient advocacy and policy / government affairs as well as supply chain, packaging and other functions.
Key clinical trial end points were met and so the executive team expanded the global team, resources and budget to deliver a successful launch.
In 2020 / 1, the 9 months of global sales of this new oral medication was 189 million euros, despite a delay in the US launch timeline.
Uptake Strategies enabled this global pharmaceutical brand to:
drive ‘a successful product launch uptake’
encourage key ‘clinical & budgetary goals uptake’
influence a significant ‘global sales uptake’